申请人长期从事胰腺癌外科基础和临床转化研究，主要成绩：⑴创新“胰肠吻合”术式，将胰瘘率由国际平均的15%下降至7%；⑵规范手术清扫范围，探索靶向攻击淋巴转移，使患者中位生存期提高约30%，达到国际先进水平；⑶建立可预测手术获益性的血清学生物标签“CEA+/CA125+/CA19-9≥1000U/mL”，甄别出“手术不获益”的胰腺癌患者亚群；⑷阐释该人群的高代谢特征和特异性分子靶点。先后主持国家自然科学基金中德国际合作项目1项、面上项目3项，入选“上海市卫生系统新百人”和“上海市启明星”等人才计划，获明治生命科学杰出奖。近5年接收/发表Ann Surg、Cell Res、CCR、Oncogene、IJC、BJS等50余篇SCI论文，作为第一发明人获5项国家发明专利，成果纳入多部胰腺癌临床指南/共识。后拟深入探索“手术不获益”胰腺癌亚群的分子机制和调控靶点，建立胰腺癌外科个体化综合治疗新策略。

The applicant's clinical practice has an emphasis on pancreatic cancer surgery and focused on the basic and translational research of the pancreatic cancer. The goal of his team includes: 1. Reduce the postoperative pancreatic fistula rate from 15% to 7% by innovating the pancreaticojejunostomy, increase the median survival time by 30% by standardizing the metastases-targeted lymphadenectomy. 2. Conduct a pre-operative serum model which would not benefit from the operation with “CEA+/CA125+/CA19-9≥1000U/mL” and reveal the metabolic characteristic and special molecular target of this group. At present, the applicant has hosted one joint Sino-German research project of national science foundation of China (NSFC) and three NSFC foundations. He was selected as “New 100 Talents of Shanghai Faulty of Health” and “Shanghai Scientific and Technological Venus Project”. He has also won the “Meiji Bioscientific Outstanding Award”. He has published over 50 SCI articles as first or corresponding author in the journals such as Ann Surg, Cell Res, Clin Cancer Res, Oncogene, Int J Cancer, Br J Surgery, Surgery and so on in the recent 5 years and achieved 5 national patents as the first inventor. Many of his achievements have been included in the diagnosis and treatment guideline of pancreatic cancer. This study will further explore the molecular mechanism and the control target of pancreatic cancer patients with poor prognosis from the surgery and establish a new therapeutic strategy of the comprehensive treatment of pancreatic cancer surgery.